1

1	AI-algorithm training and validation for endometrial CD138+ cells in infertility-
2	associated conditions; polycystic ovary syndrome (PCOS) and recurrent
3	implantation failure (RIF)
4	Seungbaek Lee <sup>1,2</sup> , Riikka K. Arffman <sup>1</sup> , Elina K. Komsi <sup>1</sup> , Outi Lindgren <sup>3</sup> , Janette A. Kemppainen <sup>3</sup> ,
5	Hanna Metsola <sup>3</sup> , Anne Ahtikoski <sup>4</sup> , Keiu Kask <sup>2,5</sup> , Merli Saare <sup>2,5</sup> ,
6	Andres Salumets <sup>2,5,6</sup> , Terhi T. Piltonen <sup>1*</sup>
7 8	<sup>1</sup> Department of Obstetrics and Gynaecology, Medical Research Center Oulu, Research Unit of Clinical Medicine, University of Oulu and Oulu University Hospital, Oulu 90220, Finland
9 10	<sup>2</sup> Department of Obstetrics and Gynaecology, Institute of Clinical Medicine, University of Tartu, Tartu 50406, Estonia
11 12	<sup>3</sup> Department of Pathology, Oulu University Hospital, Cancer and Translational Medicine Research Unit, University of Oulu, Oulu 90220, Finland
13	<sup>4</sup> Department of Pathology, Turku University Hospital, Turku 20521, Finland
14	<sup>5</sup> Competence Centre on Health Technologies, Tartu 51014, Estonia
15 16	<sup>6</sup> Division of Obstetrics and Gynaecology, Department of Clinical Science, Intervention and Technology, Karolinska Institute and Karolinska University Hospital, Stockholm 14152, Sweden
17	
18	
19	

20 \*Correspondence: Prof. Terhi Piltonen; Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Medical Research Center, Oulu University Hospital, University of Oulu, Oulu 90220, Finland; 21 22 terhi.piltonen@oulu.fi

#### Abstract 23

Immunohistochemical analysis of CD138+ plasma cells has been applied for detecting endometrial 24 inflammation, especially chronic endometritis (CE). In this study, we developed for the first time an 25 26 artificial intelligence (AI) algorithm, AITAH, to identify CD138+ plasma cells within endometrial tissue, focusing on two infertility-related conditions: polycystic ovary syndrome (PCOS) and 27 28 recurrent implantation failure (RIF). We obtained 193 endometrial tissues from healthy controls 29 (n=73), women with PCOS (n=91), and RIF patients (n=29) and compared CD138+ cell percentages across cycle phases, ovulation status, and endometrial receptivity. We trained AITAH with CD138 30 31 stained tissue images, and experienced pathologists validated the training and performance of 32 AITAH. AITAH, with high accuracy in detecting CD138+ cells (88.57%), revealed higher CD138+ cell percentages in the proliferative phase than in the secretory phase or in the anovulatory PCOS 33 34 endometrium, irrespective of PCOS diagnosis. Interestingly, CD138+ percentages differed according to PCOS phenotype in the proliferative phase (p=0.01). Different receptivity statuses had no impact 35 on the cell percentages in RIF samples. In summary, the AI-enabled analysis is a rapid and accurate 36 tool to examine endometrial tissues, potentially aiding clinical decision-making. Here, the AI analysis 37 demonstrated cycle-phase differences in CD138+ aggregations pattern, but no major alterations in 38 39 PCOS or RIF samples.

#### Introduction 40

Menstrual cycle-related fluctuations in sex hormones not only contribute to the growth and 41 degeneration of the endometrial lining but also modulate the local immune environment by regulating 42 43 innate/adaptive immune responses and endometrial immune cell populations: B and T lymphocytes, uterine natural killer (uNK) cells, plasma cells, macrophages, and dendritic cells<sup>1–3</sup>. As a sum effect, 44 cellular immunity in the endometrium is high in the proliferative phase but declines toward the mid-45 46 secretory phase, facilitating successful implantation of the semi-allogenic embryo<sup>2</sup>.

3

Endometrial plasma cells can either be recruited from the circulation or developed locally from 47 antigen-committed B cells<sup>4</sup>. CD138, a heparan sulfate proteoglycan (HSG) on the surface of plasma 48 cells, serves as a receptor for growth factors and immune mediators, attracting plasma cells to the 49 endometrium<sup>5</sup>. Endometrial CD138+ plasma cells have been used as a diagnostic biomarker for 50 endometrial inflammation, including chronic endometritis (CE)<sup>6-8</sup>, and the number of CD138+ 51 plasma cells is correlated with the severity of endometrial inflammation in women with reproductive 52 failure<sup>7–9</sup>. Identifying isolated CD138+ plasma cell aggregates without other histological features of 53 CE, such as stromal edema and increased stromal cell density, may also detect cases with potentially 54 milder inflammation and related endometrial dysfunction<sup>10</sup>. However, current quantification methods 55 56 of CD138+ cells are typically based on laborious and time-consuming microscopic assessments of only a few random areas from a sample<sup>10</sup>. These methods have limitations in accurately representing 57 the entire slide and are susceptible to significant biases arising from both intra- and inter-observer 58 variations<sup>10–12</sup>. 59

Convolutional neural networks (CNNs) are widely used to analyze histological patterns<sup>13</sup>. In 60 particular, the artificial intelligence (AI) embodied by CNNs enables rapid analysis of whole tissue 61 slides with high resolution, addressing the current limitations of manual histopathological 62 performance<sup>13</sup>. To date, this promising and potent AI technique has been increasingly applied in 63 various clinical research fields to predict the onset and progression of specific diseases<sup>14–18</sup>. Given 64 that an imbalanced inflammatory milieu has been linked to infertility-associated conditions, such as 65 polycystic ovary syndrome (PCOS)<sup>19</sup> and recurrent implantation failure (RIF)<sup>9,10</sup>, this study utilized 66 an AI algorithm to assess endometrial CD138+ cells in these two conditions. 67

PCOS is a common endocrine disorder characterized by hyperandrogenism (HA), systemic low-grade inflammation, insulin resistance, and anovulation<sup>20</sup>. The PCOS endometrium exhibits dysregulated immune profiles<sup>19</sup> and altered receptivity-related proteomic profiles<sup>19,21</sup>, which could lead to poor reproductive outcomes<sup>19,21</sup>. However, many studies lack sufficient endometrial sample dating, often

4

overlooking secretory phase samples despite occasional spontaneous ovulations and pregnancies in
 PCOS women. Moreover, although the presence of CD138+ cells varies depending on the menstrual
 cycle phase<sup>8,12</sup>, CD138+-based evaluation in PCOS endometrium across different cycle phases is
 lacking.

RIF, often defined as three or more failed in vitro fertilization (IVF) attempts with good-quality 76 embryos transferred, significantly impacts IVF success rates<sup>22</sup>. Factors from the maternal side, 77 including age, body mass index (BMI), and immunological factors<sup>22</sup>, as well as unprepared 78 endometrium for embryo implantation (e.g., shifted window of implantation, impaired 79 decidualization in stroma)<sup>23,24</sup>, have an impact on the implantation rate and reproductive 80 outcomes<sup>22,25</sup>. Moreover, CE is prevalent in RIF patients, affecting up to 14% of this population<sup>9</sup>. 81 Given the multifaceted underlying mechanisms of RIF, it is important to understand the association 82 83 between endometrial receptivity and inflammatory processes, particularly CD138+ cell clustering in 84 fully receptive samples without prominent CE.

In this study, we developed an AI algorithm, "Artificial Intelligence for Targeted Analysis of Histology" (AITAH), to detect stromal CD138+ cells, an indicator of the endometrial immune milieu. As a novel setup, we investigated the CD138+ cell occurrence to identify factors influencing the aggregation of CD138+ cells in relation to menstrual cycle phases and ovulatory status under PCOS conditions, as well as endometrial receptivity under RIF conditions.

### 90 Materials and methods

### 91 **Tissue collection**

#### 92 PCOS and control samples

A total of 164 endometrial biopsy samples from 44 healthy controls and 61 women with PCOS were
collected at the Oulu University Hospital (Oulu, Finland) from January 2017 to March 2020 (Fig 1,

5

Table 1). The study was approved by The Regional Ethics Committee of the Northern Ostrobothnia 95 96 Hospital District, Finland (65/2017), and informed consent was signed by all study subjects. All methods were carried out in accordance with relevant guidelines/regulations in line with the 97 Declaration of Helsinki. All women were non-smokers and had not used any hormonal medication 98 for at least three months prior to tissue collection. Some women gave samples in multiple phases in 99 different cycles (only one biopsy per cycle), with a maximum of three samples per individual 100 101 (depicted by multiple sample providers in Fig 1). Control women were healthy, had regular cycles, and were without PCOS symptoms. As per the international Guideline, PCOS was diagnosed 102 103 according to the Rotterdam consensus, requiring the presence of at least two of the following clinical features: oligo-anovulation (OA), HA, and polycystic ovarian morphology (PCOM)<sup>26</sup>. Some women 104 with PCOS had occasional ovulations that were traced for secretory phase sampling and analysis. As 105 for PCOS phenotype sub-analysis, PCOS women were divided based on their phenotype; 35 women 106 107 with phenotype A (PCOM+OA+HA, most severe PCOS phenotype, metabolic) and 19 with phenotype D (PCOM+OA, mildest phenotype, reproductive), were identified (Supplemental Table 108 S1)<sup>26</sup>. Endometrial biopsies were obtained by a suction curette (Pipelle), fixed in 10% formaldehyde 109 110 for hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC)<sup>27</sup>. The samples for ovulatory cycles were obtained in either the proliferative phase (PE) (cycle days 6-8) or the secretory 111 112 phase (SE) on specific days after the luteinizing hormone (LH) surge, at +2-4 days (early secretory phase (ESE)), +7–8 days (mid-secretory phase (MSE)), or +11–12 days (late secretory phase (LSE)) 113 (PE; 12 control, 24 PCOS, ESE; 15 control, 15 PCOS, MSE; 26 control, 21 PCOS, LSE; 20 control, 114 18 PCOS). The LH surge was detected using a Clearblue digital urine test in the morning, and the 115 presence of the corpus luteum was confirmed by transvaginal ultrasonography (TVUS) via Voluson 116 117 E8 (GE Healthcare Technologies, United States). The cycle phases were histologically determined 118 from the H&E-stained slides by an experienced gyneco-pathologist. In the case of anovulation

6

119 confirmed by clinical evaluation and histological analysis, 13 biopsies were obtained on any day120 convenient for the PCOS subjects.

Endometrial thickness was measured by TVUS. Serum levels of anti-Müllerian hormone (AMH), LH, follicle-stimulating hormone (FSH), and sex hormone-binding globulin (SHBG) were measured with Elecsys assays (Roche) using a cobas e411 analyzer. Serum testosterone and progesterone (P4) levels were measured at the University of Eastern Finland using an Agilent 1290 Rapid Resolution LC System (Agilent, San Jose, CA, United States)<sup>28</sup>. Free androgen index (FAI) was calculated using the formula: testosterone (nmol/L) / SHBG (nmol/L) \*100.

#### 127 *RIF samples*

128 A total of 29 RIF samples were obtained from the beREADY endometrial receptivity testing 129 laboratory (CCHT, Tartu, Estonia) from women who had undergone an average of 3.9 unsuccessful IVF cycles despite having good-quality embryos transferred (Fig 1). The study was approved by the 130 131 Research Ethics Committee of the University of Tartu, Estonia (340T-12). The requirement for informed consent for obtaining RIF samples was waived by the same Research Ethics Committee as 132 data was anonymized. All experiments were performed in accordance with relevant 133 guidelines/regulations in line with the Declaration of Helsinki. Their anonymized data and 134 endometrial biopsies were obtained prior to the subsequent IVF treatment<sup>23</sup> using a Pipelle during a 135 136 hormone replacement treatment (HRT) cycle on day 5 after initiation of P4 administration (HRT: P+5). The first day of P4 administration was considered day zero (HRT: P+0). All biopsies were 137 placed into RNAlater (Ambion, United States), and then stored at -80°C before use 138

#### 139 Endometrial receptivity testing

Gene expression profiling was conducted using the beREADY test at CCHT, involving 57 known endometrial receptivity genes along with four housekeeping genes (*SDHA*, *CYC1*, *TBP*, and HMBS)<sup>23,24</sup>. Endometrial RNA from RIF patients (n=29) was extracted using the Qiagen miRNeasy

7

Mini kit, and according to the test results, the RIF samples were divided into pre-receptive (n=9), receptive (n=10), and post-receptive (n=10) (**Table 1**).

#### 145 Immunohistochemistry

The endometrial biopsies were processed accordingly: 5-µm paraffin-embedded tissue sections of 146 controls (n=73) and women with PCOS (n=91) and 2.5-µm paraffin sections of RIF patients (n=29) 147 148 were de-paraffinized in xylene and rehydrated in different grades of alcohol. Next, antigen retrieval 149 with Tris-EDTA (pH 9) was performed in a microwave oven (800W) for 2 min. Dako peroxidase 150 blocking solution (Dako S2023) was used to neutralize endogenous peroxidase for 5 min. The 151 sections were incubated with 40x diluted mouse anti-human monoclonal antibody CD138 (MS-1793-152 S; Thermo Fisher Scientific) for 30 min at room temperature and then for 30 min with Dako EnVision polymer (Dako K5007), followed by a DAB working solution for 3 min. H&E staining was performed 153 for 15 sec. The IHC staining for both controls and PCOS samples was performed at the University of 154 Oulu (Oulu, Finland), and the staining for the RIF samples was processed at the Tartu University 155 156 Hospital Pathology Department and the University of Tartu (Tartu, Estonia). Positive and negative controls from four different human tissues (i.e., tonsils, liver, pancreas, and appendix) were used for 157 the CD138 antibody. 158

All IHC slides were scanned using a Leica SCN 400 Slide Scanner (Leica, Biosystems, United
States), and the digitalized whole slide images (WSIs) were uploaded to Aiforia cloud (Aiforia
Technologies Oy, Helsinki, Finland). Eleven slides with inadequate quality were excluded.

### 162 AITAH algorithm training

Our previous AI algorithm, AINO, was modified and trained to detect CD138+ plasma cells in the endometrial stroma<sup>16</sup>. Our current AI algorithm, AITAH, was trained using morphological features derived from 150 WSIs across two layers: the regional layer and the object layer. All training was

performed on regions of interest (ROI) drawn to remove noise and background interference that could affect the analysis. The regional layers were trained to segment the epithelium and stroma, followed by training the object layers to differentiate CD138- and CD138+ cells within the stroma. The training set consisted of a 28,363 mm<sup>2</sup> region and 7,345 object layers (6,942 CD138- cells and 403 CD138+ cells). The algorithmic structure of AITAH and the training process are shown in **Fig 2a-d**.

### 171 AITAH algorithm validation and analysis

The accuracy and reliability of the AITAH algorithm were assessed through a two-step validation by the three external validators (O.L., J.K., and H.M.) who did not take part in the AITAH algorithm training to avoid biased decisions.

The training validation was performed in 18 WSIs not used for the model training. A total of 76 ROIs 175 176 (36 regional and 40 object layers) were selected in each cycle phase and study group. The validators (O.L. and J.K.) annotated all the compartments, and the annotation was compared to the AITAH 177 algorithm (**Fig 2e-g**). The error indices were automatically calculated in the AI platform<sup>17</sup>. Briefly, 178 179 the total error indicates a sum of false negative (FN) and false positive (FP) predictions, precision is measured by dividing the true positive (TP) by all positives, sensitivity is measured by dividing the 180 TP by the sum of the TP and the FN, and the F1 score is measured by the harmonic mean of precision 181 and sensitivity. Furthermore, specificity is determined by dividing the true negative (TN) by the sum 182 of TN and FP, while accuracy is computed by dividing the sum of TP and TN by the sum of TP, FP, 183 FN, and TN. 184

In the performance validation, the validators (O.L., J.K., and H.M.) manually counted the number of stromal CD138+ cells in ten randomly selected high-power fields (HPFs) on each slide for a total of 10 slides. Since a 1-mm<sup>2</sup> unit area is equal to four HPFs<sup>29</sup>, the cell counts from AITAH analysis were divided by 4 to convert to cells/HPF format. These converted data were compared to the median number of CD138+ cells determined by the validators.

After the validation, the analysis for 182 WSI (i.e., 71 control, 82 PCOS, and 29 RIF samples) was performed. CD138+ cell percentages were calculated manually by dividing the total number of CD138+ cells by the sum of CD138- and CD138+ cells in all ROIs within a WSI, and then multiplying by 100.

#### 194 Statistical analysis

Statistical analyses were conducted using IBM SPSS Statistics v28 (IBM Corp., Armonk, NY, United 195 States), and visualization was created using GraphPad Prism (version 9.3.0) and RStudio (version 196 197 2022.12.0.353 with R version 4.2.2). For the women who had provided more than one sample, the 198 CD138+ cell percentages and clinical features were counted as individual samples in each cycle 199 phase. The cell percentages based on PCOS diagnosis and cycle phases were analyzed by the mixedmodel analysis of variance (ANOVA), in which the total variance is divided into the within-group 200 201 variance and the between-group variance. The continuous variables were tested by a Mann-Whitney 202 U test for paired tests and a Kruskal-Wallis test for multiple comparisons depending on the data 203 distribution. Statistical significance was defined as p < 0.05. An intra-class correlation (ICC) estimate was calculated using a two-way mixed effects model with an absolute agreement model, with ICC 204 values interpreted as poor (<0.5), moderate (0.5–0.75), good (0.75–0.9), and excellent (>0.9) 205 reliability<sup>30</sup>. Correlations between the CD138+ plasma cell percentages and clinical characteristics 206 207 were calculated using Spearman correlations, considering data availability and distribution.

### 208 **Results**

#### 209 Training and validating the AI-algorithm AITAH

The final training error for the regional layers (i.e., epithelium and stroma) and the object layers (i.e., CD138-/+ stromal cell) was 2.28% and 6.15% (CD138+ cells 3.23%, CD138- cells 6.32%), respectively (**Supplemental Table S2**). In the training validation, median values of precision,

sensitivity, F1 score, and specificity were calculated from 18 WSIs between pathologists 213 214 (Supplemental Figure S1a). All verification statistics for CD138+ cells were 100%, indicating that 215 the decisions made by the pathologists and the AITAH algorithm were in complete agreement. For 216 the performance validation, we compared the number of CD138+ cells quantified by the pathologists and the AITAH analysis in 10 slides (Supplemental Figure S1b). The two evaluation methods 217 showed excellent accuracy (ICC; 0.76, 95% CI; 0.36 to 0.93, p=0.002) and a positive correlation 218 (Spearman's rank correlation coefficient: 0.79, p < 0.01). The interobserver variability between 219 pathologists indicated good to excellent reliability for training validation and good reliability for 220 performance validation (Supplemental Table S3). Therefore, the AITAH algorithm demonstrated 221 222 sufficient functionality in identifying the target plasma cells.

#### 223 Endometrial stromal CD138+ plasma cell percentages by cycle phase and PCOS status

The AITAH analyzed 71 controls and 82 PCOS slide images, grouped by PCOS 224 diagnosis/phenotypes and menstrual cycle phases. CD138+ cell percentages showed a significant 225 decrease from proliferative (PE) to secretory phases, regardless of PCOS diagnosis (p < 0.001) (Fig. 226 **3a**). Moreover, we did not find any differences in the CD138+ cell proportion between control and 227 PCOS cases at the same cycle phase ( $p_{PE}=0.83$ ,  $p_{ESE}=0.22$ ,  $p_{MSE}=0.92$ ,  $p_{LSE}=0.98$ ). Interestingly, 228 229 anovulatory PCOS cases exhibited similar CD138+ cell percentages than the PCOS SE samples (p>0.58) but markedly lower than PCOS PE samples (p<0.001). In the phenotype comparisons, we 230 pooled the three secretory phases into one phase (SE) to simplify the comparisons between the cycle 231 232 phases and increase the power of statistical analysis. Phenotype A cases showed significantly higher CD138+ cell percentages compared to phenotype D cases in the PE (p < 0.001) (Fig 3b). 233

11

#### Correlations between endometrial stromal CD138+ plasma cell percentages and clinical 234 235 characteristics in women with PCOS and non-PCOS controls

To validate the correspondence between the AITAH analysis and menstrual cycle-related traits and 236 237 elucidate factors contributing to increased CD138+ cell percentages in the PE, we analyzed correlations between the plasma cell percentages and physiological features (Table 2). Control SE 238 samples showed negative correlations with P4 ( $r^2$ =-0.43, p=0.02) and positive correlations with FAI 239 and LH (FAI;  $r^2=0.45$ , p<0.001, LH;  $r^2=0.41$ , p=0.02). In contrast, PCOS SE cases exhibited positive 240 correlations with testosterone ( $r^2=0.32$ , p=0.02) and AMH ( $r^2=0.30$ , p=0.03). Meanwhile, we did not 241 observe any significant correlations in the PCOS anovulatory group. 242

#### Endometrial stromal CD138+ plasma cell percentages by receptivity in RIF samples 243

Next, we investigated potential variations in CD138+ cell percentages across distinct endometrial 244 receptivity statuses, defined by the gene expression. We utilized the endometrial samples that were 245 timed after progesterone administration at P4+5 days, which is considered the window of 246 implantation and common time for embryo transfer in assisted reproductive technology. We did not 247 observe any differences in CD138+ cell percentages between different receptivity statuses among 248 249 RIF samples (p=0.81) (Fig 4).

#### Discussion 250

In this study, we developed an AI algorithm, AITAH, for the first time, to quantify CD138+ plasma 251 cells and investigate the factors influencing the CD138+ cell aggregation in the human endometrium 252 253 without any other signs of CE. We verified that the AITAH algorithm demonstrated excellent precision and specificity compared to human analysis. Our findings align with the previous research 254 showing a higher CD138+ plasma cell presence in the proliferative phase endometrium compared to 255 the secretory phase endometrium<sup>8,31</sup>. As a novel finding, anovulatory PCOS samples showed 256

significantly lower CD138+ cell percentages compared to the PE PCOS samples, and phenotype A
PCOS samples showed higher CD138+ cell percentages in the proliferative phase than phenotype D
ones. On the other hand, the cell percentages did not show variations based on endometrial receptivity
in RIF samples.

In recent years, the advancement of deep CNN technology has revolutionized the rapid analysis of a 261 massive number of WSIs. However, the application of CNN algorithms in uterine studies has 262 predominantly focused on cancer research<sup>18,32</sup>. To our knowledge, our study was the first to target 263 endometrial CD138+ plasma cells in a whole view of slides using a cloud-based CNN platform with 264 265 high precision and specificity. As supported by previous publications, the implementation of the CNN platform enhances analysis capabilities by reducing intra- and inter-observer variations, minimizing 266 hands-on time, and improving the speed and reproducibility of analysis<sup>15,17,25</sup>. Indeed, we analyzed 267 268 182 WSIs within an hour, surpassing what could be achieved by a pathologist alone. Still, certain endometrial features posed challenges in AITAH algorithm training and analysis, particularly pre-269 decidual structures in the stroma. AITAH occasionally misidentified these structures as epithelium, 270 271 thus ignoring the stromal cells in those areas. Nevertheless, based on previous studies using the same AI platform, we evaluated the overall performance to be excellent <sup>14,15,17</sup>. 272

273 Higher CD138+ cell percentages in the proliferative phase compared to the secretory phase may be due to the estradiol-mediated recruitment of plasma cell progenitors from the systemic circulation 274 into the endometrial mucosa, supported by a mouse study<sup>33</sup>. Furthermore, as the endometrium 275 276 thickens towards the secretory phase, biopsies may predominantly contain superficial layers, resulting in lower CD138+ cell percentages relative to unstained stromal cells<sup>31</sup>. These hypotheses do not, 277 278 however, explain our results that there were fewer CD138+ cells in anovulatory and amenorrhoeic PCOS samples compared to proliferative PCOS samples, despite the similar endometrial thickness. 279 Considering that anovulatory endometrium exhibits an increased expression of estrogen receptors, 280 heightened estrogen sensitivity, and greater estrogen exposure<sup>19,34</sup>, further research with a larger 281

sample size is necessary to explore the presence of CD138+ cells in the anovulatory PCOS
endometrium. In addition, higher CD138+ percentages in PCOS phenotype A compared to D at the
beginning of a menstrual cycle (cycle days 6-8) suggest that hyperandrogenism also affects CD138+
recruitment.

Our result indicated that receptivity status at P4+5 had no effect on CD138+ cell accumulation. However, further investigation is warranted to validate previous findings suggesting an increased prevalence of endometrial inflammation (or even CE) in infertile women as assessed by CD138+ plasma cell aggregation<sup>7,8</sup> and the potential detrimental impact of HRT on immune cell profiles<sup>35</sup>. Future studies should consider larger sample sizes and incorporate prospective study designs, including women undergoing IVF treatment with natural menstrual cycles or stimulated cycles versus HRT cycles.

The main strength of our study is the reliability of our AI algorithm in identifying stromal CD138+ plasma cells within a WSI in only a few seconds. Furthermore, with the rare and well-characterized human tissue sample set, we were able to encompass diverse endometrial conditions: i) different menstrual cycle phases; ii) individuals with PCOS or RIF diagnoses; iii) both ovulatory and anovulatory cases; and iv) varying endometrial receptivity statuses.

As for limitations, we lacked confirmed CE cases as positive controls, although we did not look for overt endometritis. Additionally, the limited number of anovulatory PCOS samples may explain the absence of correlations between CD138+ plasma cell percentages and clinical characteristics, despite the exceptionally large total PCOS sample set. We lacked detailed clinical information on the RIF patients such as serum sample analysis. Lastly, in both control and PCOS populations, serum estrogen levels fell below the detection limit by LC-MS, as all steroids were analyzed in a single run and unavailable for separate analysis. Despite these limitations, our study showed the promising potential

of AI technology to address current clinical and practical challenges in detecting endometrial immune
 cells.

## 307 Conclusion

308 Our findings emphasize the accuracy and potential of AITAH algorithm in detecting endometrial 309 CD138+ plasma cells, offering distinct advantages such as rapid inspection of whole slide images, 310 independence from trained pathologists, and consistent productivity. This supports the utilization of 311 AI technology to help clinical decision-making for example in endometrial cycle phase-related 312 dynamics, as well as in different reproductive disorders.

### 313 Supplemental Data

Supplemental Figure S1. The AITAH algorithm validation result. Validation for the AITAH algorithm was carried out in two stages: (A) training validation and (B) performance validation. (A) The heatmap calculated by the median between the two validators presents the agreements between the AITAH algorithm and the validators. (B) The number of CD138+ cells per high power field (HPF) from manual counting was compared to the AITAH analysis results. The area unit (mm<sup>2</sup>) was converted to HPF (1 HPF=0.25 mm<sup>2</sup>). The validation values were calculated by the median between the three validators.

321 Supplemental Table S1. Baseline characteristics of PCOS subjects by phenotypes

- 322 Supplemental Table S2. The AITAH algorithm training results
- 323 Supplemental Table S3. Interobserver variability in the AITAH algorithm validation

### 324 **Ethics Statement**

This study was approved by The Regional Ethics Committee of the Northern Ostrobothnia Hospital District, Finland (65/2017), and the Research Ethics Committee of the University of Tartu, Estonia (340T-12). All experiments were performed in accordance with relevant guidelines/regulations in line with the Declaration of Helsinki.

#### 329 Author Contributions

330 T.T.P., A.S., R.K.A., and S.L designed the study. T.T.P., A.S., R.K.A., E.K.K., and M.S. contributed

to sample collection. A.A., K.K., and M.S. were involved in sample processing. O.L., J.A.K., and

332 H.M. performed the validation. S.L. and E.K.K. performed image analysis. S.L. and R.K.A.

333 performed the statistical analysis. All authors revised and approved the final version.

### 334 Funding

335 This research was funded by the Academy of Finland, the Sigrid Jusélius Foundation, Novo Nordisk

Foundation, and the European Union's Horizon 2020 research and innovation programme under the

337 Marie Sklodowska-Curie grant (MATER, grant no. 813707). This research was also funded by the

338 Estonian Research Council (grant no.PRG1076), Horizon 2020 innovation grant (ERIN, grant no.

339 EU952516), Enterprise Estonia (grant no. EU48695), and MSCA-RISE-2020 project (TRENDO,

grant no. 101008193). The funders did not participate in any processes of the study.

## 341 **Conflict of Interest**

The authors declare that the research was conducted in the absence of any commercial or financialrelationships that could be construed as a potential conflict of interest.

#### All rights reserved. No reuse allowed without permission.

#### Acknowledgments 344

- This study would not have been possible without the participation of all of the subjects. We thank 345
- research nurse Elina Huikari for her help in sample collection, and Riitta Vuento for her technical 346
- assistance in the IHC staining. 347

#### Data availability statement 348

- 349 The datasets generated during and/or analysed during the current study are not publicly available due
- to sensitivity of the health data. Non-personal data can be requested from the corresponding author. 350

#### 351 References

- 352 1. Lee, S. K., Kim, C. J., Kim, D.-J. & Kang, J. Immune Cells in the Female Reproductive Tract. 353 Immune Netw 15, (2015).
- 354 2. Vanderstraeten, A., Tuyaerts, S. & Amant, F. The immune system in the normal endometrium and 355 implications for endometrial cancer development. Journal of Reproductive Immunology vol. 109 356 Preprint at https://doi.org/10.1016/j.jri.2014.12.006 (2015).
- Canning, M. B. & Billington, W. D. Hormonal regulation of immunoglobulins and plasma cells in the 357 3. 358 mouse uterus. Journal of Endocrinology 97, (1983).
- 359 Kitaya, K., Takeuchi, T., Mizuta, S., Matsubayashi, H. & Ishikawa, T. Endometritis: new time, new 4. 360 concepts. Fertility and Sterility vol. 110 Preprint at https://doi.org/10.1016/j.fertnstert.2018.04.012 361 (2018).
- 362 5. Xu, Y., Mei, J., Diao, L., Li, Y. & Ding, L. Chronic endometritis and reproductive failure: Role of 363 syndecan-1. American Journal of Reproductive Immunology vol. 84 Preprint at 364 https://doi.org/10.1111/aji.13255 (2020).
- 365 Bayer-Garner, I. B., Nickell, J. A. & Korourian, S. Routine Syndecan-1 Immunohistochemistry Aids 6. 366 in the Diagnosis of Chronic Endometritis. Arch Pathol Lab Med 128, 1000–1003 (2004).
- 367 7. Chen, Y., Fang, R., Luo, Y. & Luo, C. Analysis of the diagnostic value of CD138 for chronic 368 endometritis, the risk factors for the pathogenesis of chronic endometritis and the effect of chronic endometritis on pregnancy: a cohort study. BMC Womens Health 16, 60 (2016). 369
- 370 8. Li, Y. et al. Diagnosis of chronic endometritis: How many CD138 + cells/HPF in endometrial stroma 371 affect pregnancy outcome of infertile women? American Journal of Reproductive Immunology 85, 372 (2021).
- 9. Bouet, P.-E. et al. Chronic endometritis in women with recurrent pregnancy loss and recurrent 373 374 implantation failure: prevalence and role of office hysteroscopy and immunohistochemistry in 375 diagnosis. Fertil Steril 105, 106-110 (2016).
- 376 Park, H. J., Kim, Y. S., Yoon, T. K. & Lee, W. S. Chronic endometritis and infertility. Clin Exp 10. 377 *Reprod Med* **43**, 185 (2016).
- 378 11. Puente, E. et al. Chronic endometritis: old problem, novel insights and future challenges. Int J Fertil 379 Steril 13, 250 (2020).
- 380 12. Bayer-Garner, I. B. & Korourian, S. Plasma Cells in Chronic Endometritis are Easily Identified When 381 Stained with Syndecan-1. Modern Pathology 14, 877–879 (2001).
- Bera, K., Schalper, K. A., Rimm, D. L., Velcheti, V. & Madabhushi, A. Artificial intelligence in 382 13.

383 384		digital pathology — new tools for diagnosis and precision oncology. <i>Nat Rev Clin Oncol</i> <b>16</b> , 703–715 (2019).
385	14.	Sjöblom, N. <i>et al.</i> Chronic cholestasis detection by a novel tool: automated analysis of cytokeratin 7-
385	14.	stained liver specimens. <i>Diagn Pathol</i> <b>16</b> , 41 (2021).
387	15.	Penttinen, A. <i>et al.</i> Implementation of deep neural networks to count dopamine neurons in substantia
388	15.	nigra. European Journal of Neuroscience <b>48</b> , 2354–2361 (2018).
389	16.	Kangasniemi, M. H. <i>et al.</i> Artificial intelligence deep learning model assessment of leukocyte counts
390	10.	and proliferation in endometrium from women with and without polycystic ovary syndrome. F S Sci
391		(2022) doi:10.1016/j.xfss.2022.01.006.
392	17.	Mäkelä, K. <i>et al.</i> Artificial intelligence identifies inflammation and confirms fibroblast foci as
393	17.	prognostic tissue biomarkers in idiopathic pulmonary fibrosis. <i>Hum Pathol</i> <b>107</b> , 58–68 (2021).
394	18.	Papke, D. J., Lohmann, S., Downing, M., Hufnagl, P. & Mutter, G. L. Computational augmentation
395	10.	of neoplastic endometrial glands in digital pathology displays. <i>J Pathol</i> <b>253</b> , 258–267 (2021).
396	19.	Palomba, S., Piltonen, T. T. & Giudice, L. C. Endometrial function in women with polycystic ovary
397	17.	syndrome: a comprehensive review. <i>Hum Reprod Update</i> 27, 584–618 (2021).
398	20.	Teede, H. J. <i>et al.</i> Recommendations from the international evidence-based guideline for the
399	20.	assessment and management of polycystic ovary syndrome <sup>†</sup> <sup>‡</sup> . Human Reproduction <b>33</b> , 1602–1618
400		(2018).
401	21.	Jiang, NX. & Li, XL. The Disorders of Endometrial Receptivity in PCOS and Its Mechanisms.
402	21.	Reproductive Sciences 29, 2465–2476 (2022).
403	22.	Bashiri, A., Halper, K. I. & Orvieto, R. Recurrent Implantation Failure-update overview on etiology,
404		diagnosis, treatment and future directions. <i>Reproductive Biology and Endocrinology</i> <b>16</b> , (2018).
405	23.	Meltsov, A. <i>et al.</i> Targeted gene expression profiling for accurate endometrial receptivity testing.
406		<i>medRxiv</i> (2022).
407	24.	Altmäe, S. et al. Meta-signature of human endometrial receptivity: a meta-analysis and validation
408		study of transcriptomic biomarkers. Sci Rep 7, 10077 (2017).
409	25.	Hallager, T. et al. Conventional microscopy versus digital image analysis for histopathologic
410		evaluation of immune cells in the endometrium. J Reprod Immunol 145, (2021).
411	26.	Teede, H. J. et al. Recommendations From the 2023 International Evidence-based Guideline for the
412		Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab (2023)
413		doi:10.1210/clinem/dgad463.
414	27.	Krjutškov, K. et al. Single-cell transcriptome analysis of endometrial tissue. Human Reproduction 31,
415		844–853 (2016).
416	28.	Häkkinen, M. R. et al. Simultaneous analysis by LC-MS/MS of 22 ketosteroids with hydroxylamine
417		derivatization and underivatized estradiol from human plasma, serum and prostate tissue. J Pharm
418		<i>Biomed Anal</i> <b>164</b> , 642–652 (2019).
419	29.	Burton, A. L. et al. Assessment of mitotic rate reporting in melanoma. The American Journal of
420		<i>Surgery</i> <b>204</b> , 969–975 (2012).
421	30.	Koo, T. K. & Li, M. Y. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients
422		for Reliability Research. J Chiropr Med 15, 155–163 (2016).
423	31.	Song, D. et al. Prevalence and confounders of chronic endometritis in premenopausal women with
424		abnormal bleeding or reproductive failure. Reprod Biomed Online 36, 78-83 (2018).
425	32.	Downing, M. J., Papke, D. J., Tyekucheva, S. & Mutter, G. L. A New Classification of Benign,
426		Premalignant, and Malignant Endometrial Tissues Using Machine Learning Applied to 1413
427		Candidate Variables. International Journal of Gynecological Pathology <b>39</b> , 333–343 (2020).
428	33.	McDermott, M. R., Clark, D. A. & Bienenstock, J. Evidence for a common mucosal immunologic
429		system. II. Influence of the estrous cycle on B immunoblast migration into genital and intestinal
430	24	tissues. The Journal of Immunology <b>124</b> , 2536 (1980).
431	34.	Xu, XL., Deng, SL., Lian, ZX. & Yu, K. Estrogen Receptors in Polycystic Ovary Syndrome.
432	25	<i>Cells</i> <b>10</b> , 459 (2021).
433	35.	Alfer, J. <i>et al.</i> Individual dynamics of uterine natural killer cells in natural and stimulated cycles
434		monitored using a new endometrial dating method. <i>American Journal of Reproductive Immunology</i>
435 436		<b>88</b> , (2022).
+30		

All rights reserved. No reuse allowed without permission.


18

# 437 Figure legends

### 438 Figure 1. The study subjects in the control and PCOS population

- A total of 164 endometrial biopsy samples were collected from 44 healthy controls and 61 women with PCOS. The subjects were categorized based on whether they provided a single or multiple samples. In the case of women with PCOS, the subjects were further classified depending on their ovulatory status. A total of 29 samples were collected from 29 RIF patients who underwent IVF
- treatment.

### 444 HRT (hormone replacement treatment), P4 (progesterone)




#### All rights reserved. No reuse allowed without permission.

19

#### Figure 2. Schematic overview of the AITAH algorithm and examples of training and validation. 446


(a) Structure of the convolutional neural networks (CNNs) model. CNN1 for the regional layer and 447 CNN2 for the object layer. (b)–(d) Examples of the AITAH algorithm training. The training was 448 449 done by manual annotation. Only the areas within the regions of interest (ROIs) shown as solid black lines were considered in the training. (b) original image, (c) manually annotated cells, (d) The 450 AITAH algorithm training result. CD138- cells were marked cyan, and CD138+ cells were marked 451 dark blue. (e)–(g) The training validation of the AITAH algorithm. The validation regions were 452 marked as black dotted lines. (e) Analyzed images by the AITAH algorithm (CD138- cells marked 453 454 cyan, CD138+ cells marked dark blue), (f) the validation from validator 1 (CD138- cells marked 455 green, CD138+ cells marked yellow), (g) the validation from validator 2 (CD138- cells marked pink, 456 CD138+ cells marked purple).



#### All rights reserved. No reuse allowed without permission.

### 459 Figure 3. Stromal CD138+ plasma cell percentages across PCOS status and cycle phases.


- Stromal CD138+ cell percentages for (a) controls (12 PE, 15 ESE, 25 MSE, 19 LSE) and PCOS cases (21 PE, 14 ESE, 21 MSE, 16 LSE, 11 Anovulatory) and (b) different PCOS phenotypes (Phenotype A; 12 PE, 26 SE, 8 Anovulatory, Phenotype D; 9 PE, 16 SE, 2 Anovulatory). Phenotype C was excluded due to the small sample size. The box indicates the inter-quartile range, the middle line represents the median, and the whiskers show the min-max range. \*\*\*p<0.001 when compared to the PE. The statistical differences were calculated by the mixed model ANOVA.
- 466 PE (proliferative phase), ESE (early secretory phase), MSE (mid-secretory phase), LSE (late
  467 secretory phase), SE (secretory phase)



#### All rights reserved. No reuse allowed without permission.

### 471 Figure 4. Stromal CD138+ plasma cell percentages stratified by endometrial receptivity.

The CD138+ cell percentage comparisons of RIF patient samples (9 RIF pre-receptive, 10 RIF receptive, 10 RIF post-receptive). The box indicates the inter-quartile range, the middle line represents the median, and the whiskers show the min-max range. The statistical differences were calculated by the Kruskal-Wallis test.



# 477 **Tables**

	Cycle	N	Age	<i>p</i> -val; Cycle phases <sup>a</sup>	<i>p</i> -val; Control vs.PCOS <sup>b</sup>	Ν	BMI	p-val; Cycle phases <sup>a</sup>	<i>p</i> -val; Control vs.PCOS <sup>b</sup>
Control	PE	12	32.42±3.85	0.99		12	28.51 <u>+</u> 4.83	0.24	
Ovulatory	ESE	15	32.40±6.31			15	26.87 <u>+</u> 4.43		
samples	MSE	26	32.08±5.98			26	25.38 <u>+</u> 4.69		
	LSE	20	31.95 <u>+</u> 6.09			20	27.49±5.17		
PCOS									
Ovulatory	PE	24	33.25 <u>+</u> 4.91	0.80	0.61	24	29.08±5.92	0.13	0.77
samples	ESE	15	34.64 <u>+</u> 3.59		0.44	15	29.09 <u>+</u> 5.98		0.27
	MSE	21	34.14 <u>+</u> 4.52		0.20	21	25.46 <u>+</u> 4.58		0.81
	LSE	18	34.11 <u>+</u> 4.19		0.22	18	28.46 <u>+</u> 6.05		0.54
Anovulatory samples	No	13	29.77 <u>+</u> 5.54	0.01	0.05	13	30.71 <u>+</u> 9.08	0.32	0.21
RIF	Receptivity	N	Age	<i>p</i> -val; Receptivity <sup>a</sup>		Ν	BMI	p-val; Receptivity <sup>a</sup>	
	Pre	9	38.67 <u>±</u> 5.34	0.97		9	25.68±5.47	0.87	
Receptivity samples	Re	9	39.00 <u>+</u> 5.15			10	25.87 <u>+</u> 6.02		
sumples	Post	10	37.70 <u>+</u> 6.85			10	25.47 <u>+</u> 2.87		

Table 1. Subject and sample information of age and BMI in different cycle phases and receptivity status

Age and BMI were presented as mean±standard deviation. The statistical differences were calculated by Mann-Whitney U test for comparing two groups and Kruskal-Wallis test for multiple groups. There was one missing age data point for a receptive RIF woman.

<sup>a</sup> is the statistical analysis between (i) cycle phases within the control or PCOS ovulatory group, (ii) PCOS ovulatory and anovulatory groups, or (iii) receptivity status within the RIF group. <sup>b</sup> is the statistical analysis between (i) control and PCOS ovulatory groups at the same cycle phases and (ii) control, PCOS ovulatory, and anovulatory groups. BMI (body mass index), PE (proliferative phase), ESE (early secretory phase), MSE (mid-secretory phase), LSE (late secretory phase), No (no cycle), Pre (pre-receptive), Re (receptive), Post (post-receptive).

		CD138+ percentages	Endometrial thickness (mm)	P4 (nmol/L)	Testosterone (nmol/L)	FAI	FSH (IU/L)	LH (IU/L)	AMH (ng/ml)
Control									
Control ( <i>n</i> =12)	PE	0.04 [0.01,0.11]	5.25 [4.43,5.78] (-0.16)	14.60 [1.34,33.34] (-0.035)	1.01 [0.80,1.38] (0.06)	2.20 [1.50,2.76] (0.13)	7.41 [6.68,8.75] (0.33)	7.69 [6.70,9.23] (0.19)	2.28 [1.22,4.64] (-0.40)
Control ( <i>n</i> =59)	SE	0.00 [0.00,0.01]	9.80 [8.40,11.30] (0.21)	25.35 [4.78,41.61] ( <b>-0.43</b> **)	1.17 [0.95,1.65] (-0.11)	2.00 [1.24,2.93] ( <b>0.45</b> ***)	3.68 [2.61,4.69] (0.15)	7.64 [4.82,10.34] ( <b>0.41</b> **)	2.25 [1.35,4.48] (0.06)
PCOS									
PCOS ( <i>n</i> =21)	PE	0.06 [0.03,0.10]	5.35 [4.53,6.03] (0.02)	11.21 [0.25,48.12] (0.33)	1.00 [0.83,1.77] (-0.02)	2.64 [1.87,3.22] (0.30)	6.79 [6.13,8.63] ( <b>-0.52</b> *)	9.72 [8.47,11.27] (-0.03)	5.27 [2.67,7.40] (0.24)
PCOS ( <i>n</i> =50)	SE	0.00 [0.00,0.01]	9.70 [8.00,10.50] (-0.05)	22.49 [0.37,41.06] (-0.24)	1.33 [1.00,1.68] ( <b>0.32</b> *)	2.51 [1.61,3.34] (0.09)	3.57 [2.62,5.03] (-0.03)	8.97 [5.19,13.20] (0.14)	3.68 [2.50,5.83] ( <b>0.30*</b> )
PCOS Anovulatory ( <i>n</i> =11)		0.01 [0.00,0.02]	5.60 [5.00,8.95] (0.05)	0.29 [0.26,0.33] (-0.17)	1.65 [1.24,2.49] (-0.47)	6.42 [3.34,11.82] (-0.05)	6.59 [5.65,7.59] (0.36)	16.46 [10.69,20.05] (0.03)	9.08 [5.01,12.80] (0.02)

Table 2. Correlations between the CD138+ cell percentages and endometrium thickness and hormonal values

The CD138 cell percentages and clinical characteristics presented as median with interquartile range [Q1;Q3]. The correlations are presented in brackets. *p* values were determined using log-transformed values of sex-hormone-related characteristics for the skewed data distribution. \* p < 0.05, \*\* p < 0.01, and \*\*\* p < 0.001P4 (progesterone), FAI (free androgen index), FSH (follicle-stimulating hormone), LH (luteinizing hormone), AMH (anti-Müllerian hormone)